A Phase 2 Study of Zilovertamab Vedotin With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab (R-CHP) in Diffuse Large B-Cell Lymphoma: waveLINE-007

被引：0

作者：

David, Lavie ^{[1
]}

Muhit, Ozcan ^{[2
]}

Ewa, Paszkiewicz-Kozik ^{[3
]}

Eva, Gonzalez Barca ^{[4
]}

Min, Kim Tae ^{[5
]}

Benedetta, Puccini ^{[6
]}

Siruo, Wang ^{[7
]}

Rushdia, Yusuf ^{[7
]}

Patricia, Marinello ^{[7
]}

Seog, Kim Won ^{[8
]}

机构：

[1] Hadassah Med Ctr, Jerusalem, Israel

[2] Ankara Univ, Sch Med, Ankara, Turkiye

[3] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[4] Barcelona Univ, IDIBELL, Inst Catala Oncol Hosp, Barcelona, Spain

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Azienda Osped Univ Careggi, Florence, Italy

[7] Merck & Co Inc, Rahway, NJ USA

[8] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-050

引用

页码：S31 / S32

页数：2